Denali Advisors’s Maravai LifeSciences MRVI Stock Holding History

Denali Advisors’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-91	Closed	-$1.13K	–	517
2023 Q2	$1.13K	Buy	+91	New	+$1.23K	﹤0.01%	440

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Denali Advisors's MRVI Position: Q3 2023 in Review

Denali Advisors sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 91 shares — an estimated $1.13K sold.

Denali Advisors first reported a position in MRVI in Q2 2023 and held it in 1 quarter. The position peaked at $1.13K in Q2 2023. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

Denali Advisors reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
Denali Advisors sold 91 Maravai LifeSciences shares in Q3 2023, an estimated $1.13K.
Denali Advisors first reported a position in Maravai LifeSciences in Q2 2023 and held it in 1 quarter.
Denali Advisors's Maravai LifeSciences position peaked at $1.13K in Q2 2023.
204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on Denali Advisors's 13F filing for Q3 2023, filed 19 Oct 2023.